Rapport Semestriel 2026 Valneva
Pièce jointe
94% of participants maintained seroresponse five years after a single vaccinationComparable antibody persistence observed in older (65+) and younger adultsData further reinforce IXCHIQ®'s...
Read MoreData from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging immunogenicity and efficacy signals Lyon...
Read More